- Home
- IPA vs APRE Comparison
IPA vs APRE Comparison
Compare IPA & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- APRE
- Stock Information
- Founded
- IPA 1983
- APRE 2006
- Country
- IPA Canada
- APRE United States
- Employees
- IPA N/A
- APRE N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IPA Health Care
- APRE Health Care
- Exchange
- IPA Nasdaq
- APRE Nasdaq
- Market Cap
- IPA 18.9M
- APRE 21.3M
- IPO Year
- IPA 2017
- APRE 2019
- Fundamental
- Price
- IPA $0.44
- APRE $3.25
- Analyst Decision
- IPA Strong Buy
- APRE Strong Buy
- Analyst Count
- IPA 2
- APRE 2
- Target Price
- IPA $6.00
- APRE $15.50
- AVG Volume (30 Days)
- IPA 1.1M
- APRE 15.3K
- Earning Date
- IPA 12-12-2024
- APRE 11-07-2024
- Dividend Yield
- IPA N/A
- APRE N/A
- EPS Growth
- IPA N/A
- APRE N/A
- EPS
- IPA N/A
- APRE N/A
- Revenue
- IPA $17,441,886.00
- APRE $1,310,839.00
- Revenue This Year
- IPA $4.33
- APRE $116.72
- Revenue Next Year
- IPA $35.64
- APRE N/A
- P/E Ratio
- IPA N/A
- APRE N/A
- Revenue Growth
- IPA 11.21
- APRE 130.31
- 52 Week Low
- IPA $0.35
- APRE $2.15
- 52 Week High
- IPA $2.60
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- IPA 40.98
- APRE 40.43
- Support Level
- IPA $0.40
- APRE $3.15
- Resistance Level
- IPA $0.53
- APRE $4.15
- Average True Range (ATR)
- IPA 0.07
- APRE 0.34
- MACD
- IPA 0.00
- APRE -0.12
- Stochastic Oscillator
- IPA 37.76
- APRE 13.97
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, Australia and others. The majority of its revenue is derived from United States of America.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.